Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

NCT03782064 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Funding

Conditions

Multiple Myeloma

Interventions

DRUG: Nivolumab
BIOLOGICAL: DC/myeloma fusions/GM-CSF

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]
[object Object]